CRSP - CRISPR Therapeutics AG
IEX Last Trade
40.52
-0.510 -1.259%
Share volume: 23,581
Last Updated: Fri 27 Dec 2024 02:30:14 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.33%
PREVIOUS CLOSE
CHG
CHG%
$41.03
-0.51
-1.24%
Fundamental analysis
12%
Profitability
0%
Dept financing
4%
Liquidity
75%
Performance
10%
Performance
5 Days
1.14%
1 Month
-16.97%
3 Months
-11.94%
6 Months
-27.71%
1 Year
-37.33%
2 Year
-7.14%
Key data
Stock price
$40.52
DAY RANGE
$40.00 - $41.22
52 WEEK RANGE
$40.84 - $91.10
52 WEEK CHANGE
-$36.33
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Samarth Kulkarni
Region: US
Website: crisprtx.com
Employees: 460
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: crisprtx.com
Employees: 460
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases. The company's lead product candidate is CTX001, an ex-viggered therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies.
Recent news